Boostimmune
Latest round
- Series A
Last raised
- Jun 2022
Total raised
- $13M
Investors
- 8
About Boostimmune
In 2021, the company was co-founded by Kwanghee Lee, a biotech/pharma professional, and Tadatsugu Taniguchi, an immunologist. The company operates as a drug developer focuses on anti-cancer field. Up till 2023, the company has the pipeline of 3 in the lead stage -- BIO101 (anti-TCTP antibody), BIO103 (ADC), BIO105, and three in discovery stage -- BIO104, BIO106, BIO107. The company plans to apply for a clinical trial application (IND) to the US FDA by the end of 2023.
Who invested in Boostimmune
8 investors across 1 round
See all investors in Boostimmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 23, 2022
Amount
$13M
Investors
Questions about Boostimmune
Who invested in Boostimmune?
Boostimmune has 8 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Boostimmune raised?
Boostimmune has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Boostimmune last raise money?
Boostimmune's most recent round on record is a Series A, in Jun 2022.
What does Boostimmune do?
In 2021, the company was co-founded by Kwanghee Lee, a biotech/pharma professional, and Tadatsugu Taniguchi, an immunologist.
Where is Boostimmune headquartered?
Boostimmune is headquartered in Seoul, South Korea.
Which VCs invest in companies like Boostimmune?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Boostimmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Boostimmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.